EUVIMEDEUVIMED entdecken
Systematische Übersicht

Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review

Gia Han Le, Sabrina Wong, Sebastian Badulescu, Hezekiah Au, Joshua D Di Vincenzo, Hartej Gill, Lee Phan, Taeho Greg Rhee, Roger Ho, Kayla M Teopiz, Angela T H Kwan, Joshua D Rosenblat und 2 weitere

Journal of Affective Disorders · 2024

DOI: 10.1016/j.jad.2024.03.165 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Affective Disorders, 2024. Verfasst von Gia Han Le und 13 weiteren Autor:innen. Beteiligte Einrichtung: Mood Disorder and Psychopharmacology Unit, University Health Network, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, …. Hauptthemen laut MEDLINE: Psilocybin, Lysergic Acid Diethylamide, Ketamine, Major Depressive Disorder. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: NIA NIH HHS, NIMH NIH HHS, NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Electrophysiologic measures provide an opportunity to inform mechanistic models and possibly biomarker prediction of response. Serotonergic psychedelics (SPs) (i.e., psilocybin, lysergic acid diethylamide (LSD)) and ketamine represent new investigational and established treatments in mood disorders respectively. There is a need to better characterize the mechanism of action of these agents. METHODS: We conducted a systematic review investigating the spectral signatures of psilocybin, LSD, and ketamine in persons with major depressive disorder (MDD), treatment-resistant depression (TRD), and healthy controls. RESULTS: Ketamine and SPs are associated with increased theta power in persons with depression. Ketamine and SPs are also associated with decreased spectral power in the alpha, beta and delta bands in healthy controls and persons with depression. When administered with SPs, theta power was increased in persons with MDD when administered with SPs. Ketamine is associated with increased gamma band power in both healthy controls and persons with MDD. LIMITATIONS: The studies included in our review were heterogeneous in their patient population, exposure, dosing of treatment and devices used to evaluate EEG and MEG signatures. Our results were extracted entirely from persons who were either healthy volunteers or persons with MDD or TRD. CONCLUSIONS: Extant literature evaluating EEG and MEG spectral signatures indicate that ketamine and SPs have reproducible effects in keeping with disease models of network connectivity. Future research vistas should evaluate whether observed spectral signatures can guide further discovery of therapeutics within the psychedelic and dissociative classes of agents, and its prediction capability in persons treated for depression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsilocybinLysergic Acid DiethylamideKetamineMajor Depressive DisorderHallucinogensDepressive Disorder, Treatment-ResistantHumansHealthy VolunteersElectroencephalography

Stichwörter der Autor:innen

DepressionElectroencephalographyGlutamatergic dissociativesMagnetoencephalographySerotinergic psychedelicsSpectral signatures

Substanzen

PsilocybinLysergic Acid DiethylamideKetamineHallucinogens

Autor:innen und Institutionen

  • Mood Disorder and Psychopharmacology Unit, University Health Network, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada. Ele…
  • Mood Disorder and Psychopharmacology Unit, University Health Network, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto,…
  • Brain and Cognition Discovery Foundation, Toronto, Canada. Electronic address: hezekiah.au@mail.utoronto.ca.
  • Mood Disorder and Psychopharmacology Unit, University Health Network, Toronto, Canada. Electronic address: joshua.divincenzo@uhn.ca.
  • Mood Disorder and Psychopharmacology Unit, University Health Network, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada. Electronic address: hartej.gill@utoronto.ca.
  • Mood Disorder and Psychopharmacology Unit, University Health Network, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada. Electronic address: lee.phan@uhn.ca.

Förderung

  • NIA NIH HHS
  • NIMH NIH HHS
  • NIDA NIH HHS
  • CIHR

Zitieren

APA

Le, G. H., Wong, S., Badulescu, S., Au, H., Di Vincenzo, J. D., Gill, H., Phan, L., Rhee, T. G., Ho, R., Teopiz, K. M., Kwan, A. T. H., Rosenblat, J. D., Mansur, R. B., & McIntyre, R. S. (2024). Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.03.165

Vancouver

Le GH, Wong S, Badulescu S, Au H, Di Vincenzo JD, Gill H, et al. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. Journal of Affective Disorders. 2024. doi:10.1016/j.jad.2024.03.165

BibTeX
@article{Le2024,
  author = {Le, Gia Han and Wong, Sabrina and Badulescu, Sebastian and Au, Hezekiah and Di Vincenzo, Joshua D and Gill, Hartej and Phan, Lee and Rhee, Taeho Greg and Ho, Roger and Teopiz, Kayla M and Kwan, Angela T H and Rosenblat, Joshua D and Mansur, Rodrigo B and McIntyre, Roger S},
  title = {Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review},
  journal = {Journal of Affective Disorders},
  year = {2024},
  doi = {10.1016/j.jad.2024.03.165}
}
Kostenlos starten →